Pfizer’s RSV vaccine candidate shows promise in older adults study
It is estimated that RSV infections in older adults account for 177,000 hospitalisations and 14,000 deaths each year in the US alone
Read More
Tag: Respiratory syncytial virus
Vicebio targets development of novel vaccines
Molecular clamp technology is a protein tag that stabilises a wide range of complex viral proteins
Read More
Positive topline results for nirsevimab in RSV
Monoclonal antibody reduced lower respiratory tract infections due to RSV in healthy infants
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
